Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States

Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States

<b>Background/Objectives:</b> COVID-19 vaccines have significantly reduced the mortality and morbidity associated with SARS-CoV-2. In the fall of 2021, the U.S. Food and Drug Administration amended its emergency use authorization guidelines for COVID-19 vaccines to allow the administrati...

Full description

Saved in:
Bibliographic Details
Main Authors: Mawuli Nyaku, Lara S. Yoon, Deborah Ricci, Lexie Rubens, Paige Sheridan, Monica Iyer, Thomas Zhen, Raymond A. Harvey, Ann Madsen
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Vaccines
Subjects:
COVID-19
adenovirus vaccine
booster vaccine
real-world data
real-world evidence
Online Access:https://www.mdpi.com/2076-393X/13/2/166
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items